European Metals Holdings Limited (LON:EMH) has completed its six core-hole infill drilling program at the Cinovec lithium-tin project in the Czech Republic and its CEO says the results are “excellent”. The firm’s CEO, Keith Coughlan commented: "We are very pleased that not only have we competed the planned drilling program on time and within budget, but that the results are excellent, in particular with respect to the two infill drillholes on the western part of the Cinovec South deposit.”
Amphion Innovations Plc (LON:AMP) said its wholly-owned business DataTern had its US patent infringement case against MicroStrategy and some of its customers dismissed. The reason for the dismissal was the withdrawal from the case of the firm’s legal counsel and DataTern’s inability to appoint a successor “in the short time frame set by the court”.
ImmuPharma PLC (LON:IMM) confirmed it is on track to publish top-line results from its phase III clinical trial in the first quarter of next year after it said over half the group had completed the full 12-month study assessing the performance of its potentially breakthrough treatment for lupus. In all 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor; all are now at or past the nine-month stage.
Bacanora Minerals Limited (LON:BCN) (TSXV:BCN) told shareholders today that it has secured access and surface rights for its flagship Sonora lithium project in Mexico. The firm said the move is in line with its strategy to construct an open-pit mine and large-scale beneficiation processing facility at Sonora, which is one of the world's larger lithium deposits.
Ferrum Crescent Ltd (LON:FCR) was also on the back foot after the European lead and zinc explorer announced a placing of shares with directors to raise £185,250. The company intends to use proceeds to support its lead-zinc exploration programme in North West Spain and for general working capital purposes.
Columbus Energy Resources PLC (LON:CERP) confirmed it has raised £1mln of additional equity funding, through an open offer to shareholders. The Trinidad-focused oil firm highlighted that the offer was “heavily oversubscribed”, more than three times the available number of shares on offer. A total of 20.12mln new shares will be issued, versus applications for 64.7mln.
Strategic Minerals Plc (LON:SML) has completed the first phase of drilling at the Hanns Camp, in Western Australia. The company reported that cobalt and nickel intersections were measured in 23 of 49 holes in the programme. It said that a substantial zone of anomalous mineralisation extends an area of 1,000 x 500 metres.
Genedrive PLC (LON:GDR) has terminated its agreement with Xcelris after running into further problems with the launch of MTB/RIF tuberculosis tests in India. The London-listed company cut its ties with its commercial partner in India after problems were experienced in assessing the impact of remedial action taken to address a specific sample preparation problem for the rapid molecular test for tuberculosis.
Non-executive director Steve Couldwell has been named as the new chief executive of Tissue Regenix Group PLC (LON:TRX), the regenerative medicines company. Couldwell has more than 25 years of experience in the pharmaceutical and medical device industry.
Event-driven marketing technology firm Mporium Group PLC (LON:MPM) has appointed Aleksander Øhrn as chief technology officer (CTO). He was most recently the co-founder and CTO of Cxense, a position that he held for the past seven years.
The stem cell specialist WideCells Group PLC said it has concluded a revenue-generating deal that will see its unique services sold in the Middle East, North Africa and Asia. First announced on October 11, the binding agreement with White Apex General Trading formally came into effect on Tuesday (Oct 31).
Glycotest, a portfolio company of Netscientific PLC (LON:NSCI), has been allowed a patent in China for its lead product, HCC Panel – a blood test designed to detect early-stage liver cancer. The patent expands the company's existing patent portfolio, which stands at ten previously granted or allowed patents, protecting multiple aspects of its proprietary liver disease diagnostic platform.
Caledonia Mining Corporation PLC (LON:CMCL) has raised its estimate of the mineable gold at Blanket in Zimbabwe by 6%, an upgrade that might extend the mine’s life. Steve Curtis, chief executive, said the improvement underscored the overall confidence level in Blanket's resources.
IronRidge Resources Limited (LON:IRR) has reported multiple gold intersections within trench and soil samples at Echbara in Chad, Central Africa. Further exploration is now planned for Echbara, which is 25km away from IronRidge’s Dorothe prospect in the central African country.
Rambler Metals and Mining PLC (LON:RMM) (CVE:RAB) is back on track with an upgrade to its Ming mine in Newfoundland after crusher repairs. Copper production over the quarter to September dropped 10% to 1,004 tonnes with gold output flat at 930oz.
Eco (Atlantic) Oil & Gas Ltd (LON: ECO, CVE: EOG) told investors it is advancing the Osprey lead, offshore Namibia, towards exploration drilling. The company, in a statement, revealed it is filing for Environmental Clearance Certificate (ECC) for a proposed well. Securing an ECC would represent the key clearance necessary for drilling, it added.
Thor Mining PLC (LON:THR) (ASX:THR) has advised that Paul Johnson, a non-executive director of the firm, is to exercise ten million director options at a price of 1.25p per share raising an additional £125,000 for the company.
Professor Lindy Durrant, chief scientific officer of Scancell Holdings Plc (LON:SCLP) - the developer of novel immunotherapies for the treatment of cancer - has been named as one of the 50 female leaders in UK healthcare business in BioBeat’s ‘50 Movers and Shakers in BioBusiness 2017’ report. Released annually, the report celebrates 50 outstanding women entrepreneurs and business leaders who are recognised for driving innovation in healthcare.
Capital Networks has issued a research report on OptiBiotix PLC (LON:OPTI) with analyst Rccardo Lowi concluding that a rich deal pipeline is likely to translate in to material revenue growth for the firm within 12 months.